Elan A. Cohen, PhD

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.

This clinical trial investigated whether hospitalization rates improved when patients with schizophrenia were treated via a digital medicine system (aripiprazole tablets with sensor) versus oral standard-of-care therapy.